Table 2 Baseline characteristics of the people with dementia, by setting

Age (years), mean (SD)

83.8 (6.5)

82.1 (6.5)

82.8 (6.5)

Women, n (%)

486 (75.2%)

679 (64.4%)

1165 (68.5%)

S- MMSE (range 0–30)^a,^b, median (Q1;Q3)

13 (8;17)

15 (10;20)

14 (9;19)

 Missing values

128

130

258

Katz Index (range 0–6)^a, median (Q1;Q3)

2 (1;4)

3 (2;5)

3 (1;5)

 Missing values

2

11

13

Charlson Comorbidity Index (range 0–37)^a, median (Q1;Q3)

2 (1;3)

2 (1;3)

2 (1;3)

Severity of neuropsychiatric symptoms (range 0–36)^a, median (Q1;Q3)

5.5 (3;10)

8 (4;13)

7 (3;12)

Zarit Burden Interview (range 0–88)^a, median (Q1;Q3)

21 (13;33)

31 (20.9;43)

27 (17;39.2)

 Missing values

3

3

6

Weight loss (≥4%, yes), n (%)

81 (13.0%)

211 (20.6%)

292 (17.7%)

 Missing values

25

28

53

Polypharmacy (≥5 drugs, yes), n (%)

440 (68.1%)

604 (57.3%)

1044 (61.4%)

Mean number of drugs (SD)

6.0 (3.1) [6]

5.3 (3.1) [5]

5.5 (3.1) [5]

Falls in preceding 3 months (baseline)

172 (26.7%)

215 (20.4%)

387 (22.8%)

 Missing values

3

1

4

 United Kingdom

55 (8.5%)

60 (5.7%)

115 (6.8%)

 Estonia

80 (12.4%)

145 (13.8%)

225 (13.2%)

 Finland

111 (17.2%)

157 (14.9%)

268 (15.8%)

 France

35 (5.4%)

151 (14.3%)

186 (10.9%)

 Germany

99 (15.3%)

91 (8.6%)

190 (11.2%)

 Netherlands

104 (16.1%)

165 (15.7%)

269 (15.8%)

 Spain

85 (13.2%)

155 (14.7%)

240 (14.1%)

 Sweden

77 (11.9%)

130 (12.3%)

207 (12.2%)